Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF 48 3-1 Month Momentum % is -12.47% as of Jul. 29, 2026. GuruFocus rates ZLDPF with a GF Score™ of 48/100. The stock has 3 warning signs investors should review. Among 1,387 Biotechnology companies, Zealand Pharma AS ranks better than 53.42% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Zealand Pharma AS's 3-1 Month Momentum % is -12.47%.
The industry rank for Zealand Pharma AS's 3-1 Month Momentum % or its related term are showing as below:
ZLDPF's 3-1 Month Momentum % is ranked better than 53.42% of 1387
companies
in the Biotechnology industry
Industry Median: -10.62
vs ZLDPF: -12.47
Zealand Pharma AS (OTCPK:ZLDPF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Zealand Pharma AS 3-1 Month Momentum % Related Terms
ZLDPF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 3-1 Month Momentum % falls into.
Zealand Pharma AS (OTCPK:ZLDPF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a 3-1 Month Momentum % of -12.47% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #646 out of 1387 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Zealand Pharma AS's 3-1 Month Momentum % too high?
Zealand Pharma AS's current 3-1 Month Momentum % is -12.47%. Based on the distribution chart, Zealand Pharma AS ranks #646 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zealand Pharma AS has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #646 out of 1387 companies for 3-1 Month Momentum %. This puts Zealand Pharma AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current 3-1 Month Momentum % is -12.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPF) has a current 3-1 Month Momentum % of -12.47%. The current 3-1 Month Momentum % is -12.47%. Zealand Pharma AS's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current 3-1 Month Momentum % is -12.47% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
48GF Score
Get the complete analysis for ZLDPF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
